Kornimate/medical-research-clean huggingface dataset:
omacetaxine for consolidation and maintenance

Conditions: Acute Myelogenous Leukemia (AML)

Summary: the purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (aml) in first complete remission following induction with cytarabine and an anthracycline, and also to assess the safety and tolerability of omacetaxine for maintenance in patients age 55 and older with acute aml in first complete remission following 3 consolidation courses with omacetaxine.


Eligibility criteria:
inclusion criteria: 1. diagnosis of aml including de novo, secondary, or with an antecedent hematologic disorder (ahd) according to the world health organization (who) criteria. 2. age ≥ 55 years. 3. patient eligible for standard induction chemotherapy based on eastern cooperative oncology group (ecog) performance status and vital organ function at the discretion of the treating physician. 4. patients who received 1-2 cycles of hypomethylating therapy (decitabine azacitidine) are eligible. 5. provide signed written informed consent. 6. be able to comply with study procedures and follow-up examinations. 7. be non-fertile or agree to use birth control during the study through the end of last treatment visit. 8. adequate renal and hepatic function at the time of second registration: * total bilirubin ≤ 1.5 x institutional upper limit of normal (uln); and * aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 2.5 x uln; and * serum creatinine ≤ 1.2 x uln. 9. ecog performance ≤ 2 at the time of second registration. 10. patients with a history of carcinoma in remission, on no therapy or on hormonal therapy for the adjuvant treatment of breast carcinoma or prostate carcinoma are included in the study. exclusion criteria: 1. diagnosis of acute promyelocytic leukemia (apl, french-american-british \[fab\] classification m3 or who classification of apl with t (15;17)(q22;q12), (pml/retinoic acid receptor alpha \[rara\] and variants). 2. prior treatment with omacetaxine. 3. relapsed or refractory aml. 4. investigational agent received within 30 days prior to the first dose of study drug. if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drug. 5. psychiatric disorders that would interfere with consent, study participation, or follow-up. 6. systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). 7. any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo the proposed therapy. this includes uncontrolled hypertension and uncontrolled diabetes, as cases of life threatening hyperglycemia have been reported (using continuous infusion at higher doses of omacetaxine). 8. active carcinoma requiring systemic chemotherapy or radiation therapy.
toxoplasma gondii infection in both children and adult patients with hematological malignancies

Conditions: Toxoplasmosis

Summary: toxoplasmosis is one of the most common zoonotic diseases caused by the obligate intracellular parasite, t. gondii. it affects up to one-third of the world's population horizontal transmission is mostly caused by ingestion of tissue cysts in infected meat, or through consumption of food or drink contaminated with sporulated oocysts, while vertical transmission occurs due to primary acquired maternal infection throughout pregnancy.in immunocompetent hosts, acquired infection is asymptomatic in more than 80% of cases, or is associated with fever,cervical lymphadenopathy, or myalgia. in immunocompromised patients,toxoplasmosis is always life-threatening where toxoplasmic encephalitis is the most important presentation. among those patients, the disease may be caused by a newly acquired infection, reactivation following cyst rupture, donation of a cyst-containing organ from a seropositive donor to a seronegative recipient, or reactivation of dormant infection in the recipient patients with hematological malignancy (hm), including those with acute myelogenous leukemia, and those who have undergone hematopoietic stem cell transplantation or treated with aggressive immunosuppressive regimens are at high risk of opportunistic infections the association between toxoplasmosis and cancers remains dual. most cancer patients are in a state of impaired cellular and humoral immune systems either from the primary disease, or from chemotherapy and/or radiotherapy administration. chemotherapeutic drugs work by killing both fast growing cancer cells, and healthy white blood cells causing neutropenia. so, patients receiving chemotherapy are more susceptible to toxoplasma infections. many studies have reported that the rate of reactivation of a latent t. gondii infection was higher in different types of cancers particularly those of the eye, brain, blood and breast. on the other side, t. gondii was also implicated as possible oncogenic pathogen with suggested role in induction and progression of malignant diseases. this was explained by many theories such as preventing apoptosis, enhancing the motility of dendritic cells and macrophages.


Eligibility criteria:
inclusion criteria: * this study will be conducted on a group of patients who are diagnosed as have hematological malignancies exclusion criteria: * patients with other non hematological malignancies.
comparison of the effects of tens and ctm on primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study was to compare the early and short-term effects of high-frequency transcutaneous electrical nerve stimulation (tens) versus connective tissue manipulation (ctm) in participants with primary dysmenorrhea. half of the participants received ctm, while the other half received tens.

ctm and tens each relieve dysmenorrhea pain, but they do so by different. the electrotherapy modality that is most commonly used in the treatment of dysmenorrhea is tens. it has been reported in studies that high-frequency tens is more effective in reducing pain than either low-frequency tens or placebo tens. a scan of the literature reveals that although there are differing opinions and applications related to the number and duration of ctm, it has been shown that women with primary dysmenorrhea experience reduced pain after ctm,

Eligibility criteria:
inclusion criteria: * being between the ages of 18-30 * having a diagnosis of primary dysmenorrhea exclusion criteria: * having used an oral contraceptive in the last 3 months, * having an active sexual life, * pregnancy, * having gone through childbirth, * having a neurological deficit, * any kind of systemic condition, * a diagnosed gynecological condition (pelvic inflammatory diseases, endometriosis, uterus cancers, ovarian cysts, etc.), * taking psychotherapeutic drugs.

Keywords: primary dysmenorrhea connective tissue manipulation (ctm) transcutaneous electrical nerve stimulation (tens) pain
picture of incidental calcium to understand risk estimate (picture) trial

Conditions: Coronary Artery Calcification

Summary: this is a prospective randomized controlled trial assessing the impact of notifying patients and their clinicians of an incidental finding of coronary artery calcification (cac) indicating increased cardiovascular risk. patients will be identified through completed radiology orders for non-gated, non-contrast chest ct in the appropriate clinical context and then will have an ehr screen for inclusion criteria. the presence of cac will be confirmed by a board-certified physician. eligible patients will be randomized to cac notification or usual care using a 1:1 stratified block randomization method based on baseline statin use.


Eligibility criteria:
inclusion criteria: * age 18 and above and \<85 * non-gated chest ct with cac * an encounter after july 1, 2021 with a stanford-affiliated clinician from one of the following clinics: * stanford internal medicine (includes university affiliated clinics) * stanford family medicine (includes university affiliated clinics) * non-ep cardiologist exclusion criteria: * advanced or poor-prognostic cancer * no active primary care or cardiology care at stanford health care * primary language other than english, spanish, vietnamese, cantonese, or mandarin * baseline statin or non-statin lipid lowering therapy * allergy to statin medication or identification of statin-associated muscle symptom
the mirror registry: minimally invasive intracerebral hemorrhage evacuation

Conditions: Supratentorial Hemorrhage

Summary: this registry will study the use of the aurora® surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. many methods of hematoma removal are available and will be based on surgeon preference. the impact of patient selection and time to surgery from last known well time will be explored.


Eligibility criteria:
inclusion criteria: * subject age is \> 18 * subject with a head ct that demonstrates an acute, spontaneous, primary, supratentorial ich of volume \> 20 ml, assessed via standard of care techniques * subject surgery can be initiated within 24 hours of the last known well time or, in patients with wake-up onset, within 24 hours of the time the patient awoke with symptoms. * subject has a nihss score \> 5 * subject has a baseline modified rankin scale (mrs) score ≤ 2 * subject with a ct angiography demonstrating no vascular malformation exclusion criteria: * subject has an underlying vascular lesion defined as causative source of ich * subject has a profound neurological deficit defined as fixed/dilated pupils or bilateral extensor motor posturing * subject has an infratentorial or brainstem ich * subject has a known life expectancy \< 6 months * subject has an uncorrectable coagulopathy * subject has a mechanical heart valve * subject is pregnant * subject participates in another concurrent interventional clinical trial * subject who is unable to meet study follow-up requirements
vinorelbine (oral) plus trastuzumab for 1st-line treatment of her2/neu overexpressing breast cancer

Conditions: Carcinoma Breast Stage IV

Summary: 1st-line treatment of her2/neu overexpressing breast cancer

the combination of vinorelbine and trastuzumab was demonstrated to be highly effective in several trials showing response rates in the range of 59-78%. this combination is characterized by good tolerability and can be applied for a prolonged period without the risk of major cumulative toxicity the availability of oral vinorelbine promises a further simplification of therapy. the present trial therefore investigates the safety and efficacy of a combined treatment with trastuzumab and oral vinorelbine.

Eligibility criteria:
inclusion criteria: * histologically proven, metastatic breats cancer. * her2-neu overexpression (ihc3+ or ihc2+/fish+) * written informed consent * no previous therapy with vinorelbine or trastuzumab * age \* 18 and \* 75 years * karnofsky-performance status \> 70% * life expectance 16 weeks and more * availability of at least one target lesion according to recist-criteria. target lesions need to be outside of radiation fields. bone metastases are excluded as indicator leasions * exclusion of pregnancy and adequte contraception during childbearing age. * adequate hematological, renal, and hepatic function * normal cardiac function. lvef should not be \>10% below normal. * adequate compliance to perform treatment and subsequent follow-up visits exclusion criteria: * locoregional recurrence of breast cancer only or development of contralateral breast cancer * pregnancy or lactation * symptomatic brain- or meningeal metastasis * concurrent endocrine antitumor therapy * other malignancies except basal cell cancer of the skin or in-situ carcinoma of the cervix * peripheral neuropathy \>= nci ctc grade 2. * other severel disease which preclude adequate treatment * participation in a clinical trial within the last 30 days. * psychological, familial, sociological or geographical conditions which preclude treatment according to the protocol or the planned follow-up

Keywords: navelbine herceptin oral breast cancer
a novel wound retractor combining continuous irrigation and barrier protection reduces incisional contamination and surgical site infection in colorectal surgery

Conditions: Colorectal Surgery

Summary: surgical site infection (ssi) remains a problem in colorectal surgery. strategies to reduce the incidence of ssi following colorectal surgery are important to improve overall patient outcomes, reduce healthcare-associated costs and provide value-based healthcare to surgical patients. preventing contamination of the wound through the use of barrier wound protectors or intraoperative wound irrigation has shown significant promise individually and is an ongoing focus to reduce wound infections ssi.

surgical site infection (ssi) remains a persistent and morbid problem in colorectal surgery with published rates ranging from 7 to 25%. the negative outcomes of ssi are well reported and include a significant increase in morbidity, length of hospital stay, readmissions and healthcare-associated cost. therefore, strategies to reduce the incidence of ssi following colorectal surgery are important to improve overall patient outcomes, reduce healthcare-associated costs and provide value-based healthcare to surgical patients. key to the pathogenesis of ssi is the degree of bacterial contamination of the surgical wound. preventing contamination of the wound or reducing the bacterial load through the use of barrier wound protectors or intraoperative wound irrigation has shown significant promise individually and is an ongoing strategic focus to reduce wound infections after surgery. the usage of intraoperative wound irrigation has been shown to significantly reduce the risk of ssi via multiple rtc. a surgical device that combines continuous wound irrigation and barrier protection will have an important ssi prevention advantage. cleancision is a recently developed apparatus that serves this purpose and was found to reduce bacterial wound contamination in preclinical and clinical trials. this study aims to investigate the effect of using cleancision wound protector on the rates of postoperative surgical site infections in comparison to the current wound protector (alexis o) being used at our institute.

Eligibility criteria:
inclusion criteria: 1. patients 18 years old and above. 2. elective colorectal surgery with a planned resection including open or laparoscopic surgeries. 3. clean -contaminated, contaminated and dirty wounds per the definition above. 4. patients undergoing standard of care ssi reduction bundle including prophylactic ab and mechanical bowel preparation. 5. anticipated incision length of 3-17 cm exclusion criteria: 1. patients younger than 18 years old. 2. patients with a preexisting stoma. 3. patiens with prior laparotomy within 15 days. 4. patients with an active infection or systemic antibiotic therapy within 1 week prior to surgery with the exception of preoperative antimicrobial prophylaxis. 5. emergent/ urgent surgery.

Keywords: wound irrigation cleancision colorectal surgery
photobiomodulation therapy (pbmt) in patients with low back pain (lbp)

Conditions: Low Back Pain

Summary: low back pain (lbp) is a highly prevalent condition worldwide and the leading cause of years lived with disability. in most cases, the specific pathological cause remains unidentified; therefore, the term non-specific low back pain is commonly used for such cases. many non-pharmacological therapies are available for the treatment of low back pain aiming to reduce pain and disability. among these options, photobiomodulation therapy (pbmt) it seems to be an interesting alternative. pbmt is a non-thermal and non-invasive clinical treatment, which has shown effects in decreased pain, modulation of inflammatory process, and tissue repair in musculoskeletal disorders. therefore, the aim of this project is to evaluate the effects of the pbmt against placebo on pain intensity in patients with chronic non-specific low back pain.

to achieve the proposed objective, it will be performed a randomized, triple-blind (patients, therapists, and outcome assessors), placebo-controlled trial. seventy-two patients with chronic non-specific low back pain will be randomly allocated to two treatment groups: 1. active pbmt or placebo pbmt. in both groups, six treatment sessions will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period. the patients will be treated by a blinded therapist. the outcomes will be obtained at stabilization phase (during 2 weeks), baseline, end of treatment, 24, 48 and 72 hours after the last treatment session, and 7 days after conclusion of treatment. the data will be collected by a blinded assessor. statistical analyzis: * the fischer's exact test will be conducted to compare the proportion of successes between groups. * the unpaired t-test will be used for demographic data. * repeated measures anova will be performed to analyze pain intensity. the level of statistical significance will be set at p\<0.05.

Eligibility criteria:
inclusion criteria: * patients with chronic non-specific low back pain, with symptoms present for at least three months; * patients with a pain intensity of at least 50mm (measured by a 0-100 mm visual analog scale); exclusion criteria: * serious spinal pathologies (such as fractures, tumors, inflammatory, and infectious diseases); * patients who used local corticosteroids and/or botulin toxin injection for pain relief within the prior 30 days of the beginning of the study; * chronic pain diseases as fibromyalgia and diabetic type 1; * neuropathic pain; * previous spinal surgery in the past 12 months; * cancer patients; * pregnancy or breast feeding.

Keywords: photobiomodulation therapy
sars-cov-2 associated respiratory failure recovery (covid-19 cair)

Conditions: SARS-CoV 2; COVID

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is the cause of the current pandemic of coronavirus disease (covid-19) that can lead to respiratory failure requiring oxygen therapy. some patients develop acute respiratory distress syndrome (ards) and may die despite intensive care therapy. currently it is unknown a) how fast patients recover after being discharged from hospital and b) what underlying predictors may influence recovery.

study aims: * to evaluate subjective and objective recovery after discharge from hospital in patients with respiratory failure due to covid-19. * to identify risk factors for covid-19 associated respiratory failure and prolonged recovery

Eligibility criteria:
inclusion criteria: * hospitalization at university hospital zurich due to covid-19 infection * hospital discharge max. 4 weeks ago * requiring supplemental oxygen exclusion criteria: * \<18 years * non-german speaking * no smartphone access
arthroscopic release of shoulder internal rotation contracture in brachial plexus palsy

Conditions: Arthroscopy

Summary: the purpose of this study is to evaluate the efficacy periarticular capsuloligamentous arthroscopic release of shoulder internal rotation contracture in brachial plexus palsy without any further intervention as tendon transfer.

obstetrical brachial plexus paralysis (obpp) refers to complete or partial injury of the brachial plexus produced at the time of birth. obpp involves most commonly the upper cervical roots (c5, c6) resulting in muscle imbalance between internal and external rotators of the shoulder . although the majority of the patients (80-90%) recover spontaneously, some have a remaining imbalance causing severe functional impairment . in addition to diminished function, prolonged muscle contractures result in bony deformities in both the glenoid and proximal humerus. internal rotation contractures due to external rotational weakness are the most common deformity in obpp. contracture release, tendon transfers, and rotational osteotomies are surgical methods used, depending on the level of deformity and the patient's age. to achieve functional external rotation of the arm, contracted structures should be released first. currently, there is a lack of consensus on which procedures over the best outcome for mobility and function, and what are the precise indications for each type of surgery. there is also a large variation of practice between centers

Eligibility criteria:
inclusion criteria: * children from 1 year to 15years of age. * all genders * patients with brachial plexus injury operated or not with internal rotation contracture * patient with traumatic brachial plexus injury have residual internal rotation contracture exclusion criteria: * history of septic shoulder * flail anaethetic limb * glenohumeral posterior sublaxation or dislocation in ct
insulin glargine for diabetes metabolism(dm)type ii patients under enteral nutrition

Conditions: Diabetes Mellitus, Type 2

Summary: primary objective: 1- proportion of patients with mean daily glycemia \<140mg/dl during the period of 7 days of treatment with glargine plus supplemental glulisine versus patients with glulisine sliding scale. secondary objective: 1. incidence of moderate hyperglycemia (\>140mg/dl) during the treatment period. 2. incidence of hypoglycemia (\<60mg/dl and \< 40mg/dl) during the treatment period. 3. incidence of severe hyperglycemia (\>400mg/dl) during the treatment period. 4. total dose of insulin and correction dose in each group.


Eligibility criteria:
inclusion criteria: * men and women with type 2 diabetes that will need enteral nutrition with carbohydrate content. * glycemia \>140mg/dl and \< 400mg/dl at admission on the ward. * informed consent (patient or legally authorized representative) exclusion criteria: * hypersensibility to insulin glargine or glulisine, or any other component of the insulin formulation. * use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months. * history of diabetic ketoacidosis or hyperosmolar hyperglycaemic state or ketonuria. * subjects with conditions that are expected to need surgery or intensive care unit (icu)admission based on discussions with the treatment team and attending physician. * pregnancy. * severe hepatic disease or active hepatitis. * cardiac failure class iii or iv (classification de la new york heart association:nyha). * diagnosed advanced autonomic neuropathy. * diagnosed cancer. * active infection. * current therapy with steroids. * patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.